Last reviewed · How we verify
T-2345
T-2345 is a small molecule drug that targets the renin-angiotensin system.
T-2345 is a small molecule drug that targets the renin-angiotensin system. Used for Hypertension.
At a glance
| Generic name | T-2345 |
|---|---|
| Sponsor | Nephron Pharmaceuticals Corporation |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
T-2345 works by inhibiting the angiotensin-converting enzyme (ACE), which plays a key role in regulating blood pressure. This leads to a decrease in angiotensin II levels, resulting in vasodilation and a reduction in blood pressure.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T-2345 CI brief — competitive landscape report
- T-2345 updates RSS · CI watch RSS
- Nephron Pharmaceuticals Corporation portfolio CI